Anika Therapeutics stockholders approve 350,000-share increase to equity incentive plan
At its June 18, 2026 annual meeting, Anika Therapeutics stockholders approved an increase of 350,000 shares to the 2017 Omnibus Incentive Plan, raising the reserve from 5,760,000 to 6,110,000 shares, and a 200,000-share increase to the 2021 Employee Stock Purchase Plan, raising its reserve to 400,000 shares. The votes also re-elected three Class III directors and ratified Deloitte & Touche LLP as the independent auditor for fiscal 2026, so shareholders should note the larger pool of shares available for future grants and purchases.
Key points
- Annual meeting held June 18, 2026; shares representing 84.14% of the voting power entitled to vote were present in person or by proxy.
- Revised Seventh Amended Plan approved with 8,013,994 votes for and 1,347,970 against; reserve rises from 5,760,000 to 6,110,000 shares.
- ESPP amendment approved with 9,110,892 votes for and 257,394 against; reserve rises from 200,000 to 400,000 shares.
- Gary P. Fischetti, John B. Henneman, III and Stephen D. Griffin elected as Class III directors to serve until the 2029 annual meeting.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 23, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.